Composition for treating glaucoma and method for producing composition for treating glaucoma
A composition using andrographolide and related compounds addresses the challenge of treating glaucoma by lowering intraocular pressure and improving visual field impairments by crossing the blood-retinal and blood-brain barriers to target the retina and optic nerve.
Patent Information
- Application Number
- JP2022080291
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2021-05-16
- Filing Date
- 2022-05-16
- Publication Date
- 2024-12-05
- Estimated Expiration
- 2042-05-16
AI Technical Summary
Current treatments for glaucoma, including high-tension and normal-tension forms, are inadequate in effectively reducing intraocular pressure and improving visual field impairment, particularly due to the challenges of crossing the blood-retinal and blood-brain barriers to reach the retina and optic nerve.
A composition comprising andrographolide (diterpene lactone) and other related compounds, mixed with water, alcohol, or oils at room temperature, which can pass through these barriers to treat and improve glaucoma by lowering intraocular pressure and reducing optic nerve and visual field damage.
The composition effectively reduces intraocular pressure to normal levels and improves visual field abnormalities by reaching the retina and optic nerve, treating glaucoma and preventing further damage.
Smart Images

Figure 0007594748000014 
Figure 0007594748000015 
Figure 0007594748000016
Abstract
Description
[Technical field]
[0001] The present invention relates to a composition for treating glaucoma and a method for producing the composition for treating glaucoma, and in particular to a composition for treating glaucoma that can treat not only high-tension glaucoma but also normal-tension glaucoma and other types of glaucoma, and a method for producing the composition for treating glaucoma. [Background technology]
[0002] Glaucoma is a condition where the pressure in the eyeball (intraocular pressure) is abnormally high. There are various causes, but overwork and lack of sleep can also be triggers. The condition can cause blurred vision, rainbow ring vision (seeing rainbow-like rings around lights), eye pain, headaches, and in severe cases, blindness. It is so named because the color of the pupils of the eyes that have lost their vision appears green. It is also called "blue-eyed eye."
[0003] Types of glaucoma include high-tension glaucoma, in which intraocular pressure is 21-22 mmHg or higher, as well as normal-tension glaucoma, in which visual field impairment occurs even though the intraocular pressure is within the normal range of 10 mmHg to 20 / 21 mmHg. In addition to open-angle glaucoma, which includes high-tension and normal-tension glaucoma, there is also angle-closure glaucoma. Furthermore, there is primary glaucoma, which includes open-angle and angle-closure glaucoma, as well as secondary glaucoma and congenital glaucoma.
[0004] Most open-angle glaucoma, including the above-mentioned high-tension glaucoma and normal-tension glaucoma, is a chronic glaucoma in which visual field impairment progresses slowly. The above-mentioned angle-closure glaucoma is an acute glaucoma in which intraocular pressure rises suddenly due to the closure of the angle of the cornea, which is the outlet for aqueous humor inside the cornea. If treatment is delayed, it can lead to blindness, and emergency treatment is required.
[0005] The secondary glaucoma is caused by trauma, corneal disease, retinal detachment, brain disease, diabetes, uveitis, eye inflammation, increased intraocular pressure due to eye disease, or increased intraocular pressure due to drugs such as steroid hormones.
[0006] Congenital glaucoma includes early developmental glaucoma, which occurs within the first year of life, late developmental glaucoma, which occurs in the teens and twenties, and other conditions such as aniridia, Sturge-Weber syndrome, and Peters anomaly. Symptoms include excessive tear production, eyelid spasms, enlargement of the iris, whitish cloudiness of the iris, and abnormal aversion to light.
[0007] In addition, the above-mentioned abnormal intraocular pressure was defined as 21 to 22 mmHg or higher. Although this is an indicator for diagnosis, there are individual differences, and some people have no abnormalities in their visual field even with a pressure of 21 to 22 mmHg or higher, while others have abnormalities in their visual field even with a pressure of 21 to 22 mmHg or lower. There is a large degree of individual variation, and it is not possible to make generalized statements. [Prior art documents] [Patent documents]
[0008] [Patent Document 1] JP 2020-121959 A [Patent Document 2] JP 2019-081741 A [Patent Document 3] Japanese Patent Application Publication No. 10-029927 [Patent Document 4] JP 2010-013400 A [Patent Document 5] China Patent Application Publication No. 102058502 [Patent Document 6] JP 2000-143437 A [Patent Document 7] Journal of Ethnopharmacology, 2004, vol.92, p.281-289 [Patent Document 8] Patent No. 6245786 [Patent Document 9] Patent No. 6225113 [Patent Document 10] Patent No. 6537147 [Patent Document 11] Patent No. 5765687 [Patent Document 12] WO2004 / 091630 publication [Patent Document 13] Patent No. 5357027 DISCLOSURE OF THEINVENTION [Problem to be solved by the invention]
[0009] The present invention has been made to solve the above-mentioned problems, and an object of the present invention is to provide a composition for treating glaucoma that can treat the above-mentioned glaucoma, and a method for producing the composition for treating glaucoma. In this application, "treatment" includes not only curing glaucoma lesions, but also improving the disease of glaucoma, treating / ameliorating glaucoma, stopping the progression of glaucoma, and slowing the progression of glaucoma. [Means for solving the problem]
[0010] Therefore, in the composition for treating glaucoma and the method for producing the same of the present invention, andrographolide (diterpene lactone) is mixed almost uniformly with water, alcohol or oils and fats that are liquid at room temperature. Effect of the Invention
[0011] This improves the visual impairment caused by glaucoma and treats glaucoma. Andrographolide (diterpene lactone) is administered orally or added to the eyeball, such as near the pupil of the eyeball. The above-mentioned andrographolide (diterpene lactone) passes through the blood-retinal barrier or blood-brain barrier to reach the retina of the eyeball and reach the brain, such as the optic nerve, to treat the part of the retina of the eyeball that is suffering from optic nerve damage or visual field damage, and to reduce intraocular pressure in the eyeball. [Brief description of the drawings]
[0012] [Figure 1] Showing improvement in the extent of visual field abnormalities before and after treatment (M). [Diagram 2] Shows improvement in the extent of visual field abnormalities before and after treatment (N). [Diagram 3]Shows improvement in the extent of visual field abnormalities before and after treatment (O). [Figure 4] Showing improvement in the extent of visual field abnormalities before and after treatment (P). [Diagram 5] Shows improvement in the extent of visual field abnormalities before and after treatment (Q). [Figure 6] Shows improvement in the extent of visual field abnormalities before and after treatment (R). [Figure 7] Shows improvement in the extent of visual field abnormalities before and after treatment (S). [Figure 8] Showing improvement in the extent of visual field abnormalities before and after treatment (T). [Figure 9] Shows improvement in the extent of visual field abnormalities before and after treatment (U). [Figure 10] Shows improvement in the extent of visual field abnormalities before and after treatment (V). [Figure 11] Shows improvement in the extent of visual field abnormalities before and after treatment (W). [Figure 12] Shows improvement in the extent of visual field abnormalities before and after treatment (X). [Figure 13] Shows improvement in the extent of visual field abnormalities before and after treatment (Y). [Figure 14] Shows improvement in the extent of visual field abnormalities before and after treatment (Z). [Figure 15] Shows improvement in the extent of visual field abnormalities before and after treatment (a). BEST MODE FOR CARRYING OUT THEINVENTION
[0013] (1) Extraction of andrographolide (diterpene lactone) etc. (production method) Andrographolide (diterpene lactone) (also called andrographolide) is mainly extracted from Andrographis paniculata, an annual plant of the Acanthaceae family, a herb native to India and Sri Lanka, and is also called sambirot.
[0014] The panicle is a medium-sized annual plant that grows to a height of about 20cm to 1m and is widely distributed from Southeast Asia to China. It produces many flowers on cone-shaped panicle inflorescences at the end of the stem, each flower being about 1cm in diameter and white with reddish purple spots. The fruit is a capsule about 2cm long and contains about 10 orange seeds.
[0015] The leaves, stems and roots of Panax paniculata are mainly used for the medicinal purposes of this invention, but sometimes the whole plant is used. It grows in moist shady places and can reach 30-110cm. All parts of Panax paniculata, including the roots and leaves, are very bitter, and it is called the king of bitter in India. As an Ayurvedic herb, it is known as karmeg, or sometimes called the "gall of the earth."
[0016] In the extraction of andrographolide (diterpene lactone), etc., the leaves, roots, stems, and flowers of Andrographis paniculata, especially the leaves, are washed, disinfected and sterilized at room temperature, then cut into small pieces, and further ground and pulverized in a grinder, crusher, powder machine, etc. to obtain a powder, powdered or granular form with a particle size of about several mm to 0.0001 mm, for example, 1 mm to 0.01 mm. In some cases, it is enclosed in capsules such as gelatin. After the above grinding or pulverization, if the moisture content is equal to or greater than a predetermined ratio, it may be dried.
[0017] This powder, shredded or granulated form of Andrographolide contains the following compounds: Andrographolide (diterpene lactone), 14-deoxyandrographolide, neoandrographolide, 14-deoxy-11,12-didehydroandrographolide, 14-deoxy-14,15-dehydroandrographolide, andrographin, isoandrographolide, 14-acetylandrographolide, 3,19-isopropylideneandrographolide, 5-hydroandrographolide, 14-hydroxy ... It contains 5-hydroxy-7,8-dimethoxyflavanone, 5-hydroxy-7,8,2',5'-tetramethoxyflavanone, and 5-hydroxy-7,8,2',3'-tetramethoxyflavanone.
[0018] To separate and extract these 15 (16) types of substances individually, for example, chromatography is used. This type of chromatography uses an appropriate stationary phase and mobile phase, through which a sample of a mixture of multiple substances in gas or liquid is moved, and by utilizing the difference in the moving speed due to the differences in the adsorption properties, distribution coefficients, mass, and charge of each substance and component, the multiple substances in the mixture are separated and extracted one by one by time differences, etc. Depending on whether the mobile phase is liquid or gas, it is divided into liquid chromatography and gas chromatography.
[0019] The above-mentioned raw or dried plants of Panax paniculata are finely cut or powdered, and the above-mentioned 15 (16) components of Panax paniculata are extracted with solvents such as purified water, alcohol, acetone, petroleum ether, ethyl acetate, etc. By switching between these solvents, the amount of each of the 15 (16) components changes slightly.
[0020] When the solvent in which these 15 (16) components have dissolved is sent to a chromatography device, each of the 15 (16) components is separated and isolated in sequence at a specified time interval. These isolated components are liquid, and can be turned into solids by drying them by heating or other methods. This type of chromatography includes high-performance liquid chromatography, high-performance fractionation liquid chromatography, high-performance thin-layer chromatography, microemulsion electrokinetic capillary chromatography, micellar electrokinetic capillary chromatography, and high-speed countercurrent chromatography.
[0021] Of the above compounds, the powder, powdered or granular form having a particle size of a few mm to 0.0001 mm, for example 1 mm to 0.01 mm, or the leaves of the above-mentioned Oriental Rainforest, are immersed directly in water, alcohol, oil, acetone, petroleum ether or ethyl acetate at 5°C to 100°C, and the andrographolide components are precipitated.
[0022] The oil may be liquid under heated or normal temperature conditions. Also, the leaves, roots, stems, flowers, especially the leaves, of the Oriental schizophrenia are finely cut or ground, and then put into normal or heated water, alcohol, liquid, acetone, petroleum ether, or ethyl acetate oil, and the components such as andrographolide are precipitated, dissolved, and purified.
[0023] This water may be at room temperature, between 0°C and 30°C. By soaking in this water, andrographolide (diterpene lactone) and other substances contained in the Chinese lantern plant are dissolved in the water and extracted, and andrographolide (diterpene lactone) and other substances are purified.
[0024] The andrographolide (diterpene lactone)-containing or extracted andrographolide-containing extract is usually filtered and discarded from water, alcohol, oil, acetone, petroleum ether, or ethyl acetate, but may be left in water, alcohol, oil, acetone, petroleum ether, or ethyl acetate. In this case, the amount of water, alcohol, oil, acetone, petroleum ether, or ethyl acetate is adjusted so that 0.0001% to 99.9999% by weight of andrographolide-containing extract is mixed with 0.001% to 99.9999% by weight of water, alcohol, oil, acetone, petroleum ether, or ethyl acetate.
[0025] In this case, the proportion of water, alcohol, oil, acetone, petroleum ether, and ethyl acetate is reduced by evaporation, and the proportion of water, alcohol, oil, acetone, petroleum ether, and ethyl acetate is increased by adding the water, alcohol, oil, acetone, petroleum ether, and ethyl acetate. Two or more of water, alcohol, oil, acetone, petroleum ether, and ethyl acetate may be mixed. In this case, the proportion of water may be the most, or the proportion of alcohol may be the most, or the proportion of oil may be the most, or the proportion of acetone, or the proportion of petroleum ether, or the proportion of ethyl acetate may be the most.
[0026] Also, it could be the least amount of water, the least amount of alcohol, the least amount of oil, the least amount of acetone, the least amount of petroleum ether, the least amount of ethyl acetate, etc. The order of abundance can be water → alcohol → oil → acetone → petroleum ether → ethyl acetate, water → oil → alcohol → acetone → petroleum ether → ethyl acetate, alcohol → oil → water → acetone → petroleum ether → ethyl acetate, alcohol → water → oil → acetone → petroleum ether → ethyl acetate, oil → water → alcohol → acetone → petroleum ether → ethyl acetate, oil → alcohol → water → acetone → petroleum ether → ethyl acetate, oil → alcohol → water → acetone → petroleum ether → ethyl acetate, or any other order.
[0027] If the amount of water, alcohol, oil, acetone, petroleum ether, or ethyl acetate is high, the composition for treating glaucoma is usually liquid. If the amount of water, alcohol, oil, acetone, petroleum ether, or ethyl acetate is low, the composition for treating glaucoma is in a sol or gel state. If the amount of water, alcohol, oil, acetone, petroleum ether, or ethyl acetate is almost zero, the composition for treating glaucoma is in a powder, powder, or granular form, and may be in the form of granules, capsules, tablets, etc.
[0028] The water may be either soft water or hard water, which is harmless to animals or the eyes of animals, and is mixed almost uniformly with a drug such as a composition for treating glaucoma at 0.001% to 99.999% by weight, and may be emulsified in some cases. The alcohol may be ethanol or cetanol, which is harmless to animals or the eyes of animals, and is mixed almost uniformly with a drug such as a composition for treating glaucoma at 0.001% to 99.999% by weight, and may be emulsified in some cases.
[0029] The oil is an oil that is harmless to animals or animal eyes, such as soybean oil, corn oil, sesame oil, olive oil, sunflower oil, etc., and is mixed almost uniformly with the drug, such as 0.001% to 99.999% by weight, and optionally emulsified, in the composition for treating glaucoma.
[0030] The extraction solvent used in the above extraction step may be water, a hydrophilic organic solvent that is harmless to animals or the eyes of animals, or a mixture of water and a hydrophilic organic solvent. Examples of hydrophilic organic solvents include lower alcohols such as methanol and ethanol, acetone, and ethyl acetate. The extraction method may be any of the known extraction methods, such as cold water extraction, warm water extraction, hot water extraction, and steam extraction.
[0031] In this extraction operation, andrographolide (diterpene lactone) is immersed in an extraction solvent for a predetermined time. In the extraction operation, in order to increase the extraction efficiency, further treatments such as stirring, pressurization, and ultrasonication may be performed as necessary, and a surfactant that is harmless to animals or the eyes of animals may be added. After the extraction operation, the extract and the raw material residue may be separated by a solid-liquid separation operation using a known separation method such as filtration or centrifugation, or they may be left mixed together. At this time, the obtained extract (extract) may be concentrated as necessary.
[0032] Such andrographolide (diterpene lactone) is made into an oral composition and taken orally. In addition, it is diluted 10 to 10,000 times to make an external composition for eye use, and used as an eye drop that is added to the eyeball, such as near the pupil of the eye. The concentration of andrographolide (diterpene lactone) in the oral composition is higher than the concentration of andrographolide (diterpene lactone) in the external composition for eye use, but it may be the same or lower.
[0033] (2) Methods for producing andrographolide (diterpene lactone) The above-mentioned andrographolide (diterpene lactone) is extracted from Andrographis paniculata, an annual plant with branches and leaves that grows abundantly in Southeast Asian countries such as India, Pakistan, Sri Lanka, and Indonesia, and is 0.5 to 1 m tall. The leaves, stems, roots, and seeds of Andrographis paniculata are used to extract the above-mentioned active ingredients, and the leaves contain a high level of Andrographolide (diterpene lactone) of 2.39%.
[0034] The Chinese sedge is cultivated from seeds and grows in evergreen, pine and deciduous forests, as well as along farm roads, but is also cultivated artificially. It can grow in any soil type, but is the only plant that grows in "serpentine soils" that contain aluminum, copper, tin and zinc. Because of its ability to grow in such soil environments, the Chinese sedge is found growing in a wide area, including China, Thailand, the East and West Indies, and Mauritius.
[0035] High performance liquid chromatography (HPLC) is used to measure the content of andrographolide and other substances. HPLC uses a tubular column filled with very small beads to separate and collect specific components from a liquid mixture sample, and this technology is used to obtain andrographolide and other substances contained in an extract obtained from the leaves and stems of Panax notoginseng. Using this technology, standardized products that always contain a consistent amount of andrographolide and other substances can be produced.
[0036] The compounds of "Chemical Formula 1" to "Chemical Formula 13" described below are all contained in the above-mentioned powdered, powdered or granular state or extracted or isolated from Andrographis paniculata in exactly the same manner as the above-mentioned andrographolide (diterpene lactone) and in the same manner as described in (1) above. In addition to having the efficacy and effects shown below, they are used to treat and improve glaucoma and are made into oral compositions or external ophthalmic compositions.
[0037] The compounds of "Chemical Formula 1" to "Chemical Formula 13" are andrographolide (diterpene lactone), 14-deoxyandrographolide, neoandrographolide, 14-deoxy-11,12-didehydroandrographolide, 14-deoxy-14,15-dehydroandrographolide, andrographin, isoandrographolide, 14-acetylandrographolide, 3,19-isopropylideneandrographolide, 5-hydroxy-7,8-dimethoxyflavone, 5-hydroxy-7,8,2',5'-tetramethoxiflavone, and 5-hydroxy-7,8,2',3'-tetramethoxiflavone, respectively.
[0038] In this application, compounds such as andrographolide (diterpene lactone) contained in or extracted from Andrographolide paniculata are collectively referred to as "andrographolide (diterpene lactone), etc.", and compounds excluding andrographolide (diterpene lactone) from these compounds are collectively referred to as "14-deoxyandrographolide, etc."
[0039] The plant containing andrographolide (diterpene lactone) is washed, disinfected, and sterilized as described above, then cut into small pieces, ground and crushed, and optionally dried to form a powder, powder, or granules having a particle size of about several mm to 0.0001 mm, for example, 1 mm to 0.01 mm. This powder, powder, or granule contains 15 (16) kinds of ingredients, including the above-mentioned andrographolide (diterpene lactone). This is the method for producing a composition for treating glaucoma.
[0040] Alternatively, the 15 (16) components can be separated and individually produced using the above chromatography device. This is also a method for producing a composition for treating glaucoma. The above plant is immersed in water, alcohol, oil, acetone, petroleum ether, and ethyl acetate as described above, thereby extracting andrographolide (diterpene lactone) and other components contained in the plant into water, alcohol, oil, acetone, petroleum ether, and ethyl acetate. The andrographolide (diterpene lactone) and other components contained or extracted in this manner are thoroughly and almost uniformly mixed with a stirrer or the like in a range not exceeding 100% by weight in total. This is also a method for producing a composition for treating glaucoma.
[0041] This composition for treating glaucoma further contains or is mixed with "14-deoxyandrographolide, etc.", i.e., 14-deoxyandrographolide, neoandrographolide, 14-deoxy-11,12-didehydroandrographolide, 14-deoxy-14,15-dehydroandrographolide, andrographin, isoandrographolide, 14-acetylandrographolide, 3,19-isopropylideneandrographolide, 5-hydroxy-7,8-dimethoxyflavone, 5-hydroxy-7,8,2',5'-tetramethoxyflavone, and 5-hydroxy-7,8,2',3'-tetramethoxyflavone.
[0042] These "14-deoxyandrographolide, etc." are also contained in the above-mentioned "Andrographis paniculata" and are produced, contained or extracted by the same production method as the above-mentioned andrographolide (diterpene lactone), and are produced, contained or extracted in parallel with the production of andrographolide (diterpene lactone).
[0043] Plants containing 14-deoxyandrographolide, especially Panax notoginseng, are similarly immersed in water, alcohol, oil, acetone, petroleum ether, or ethyl acetate, and the "14-deoxyandrographolide, etc." contained in the plant is extracted in water, alcohol, oil, acetone, petroleum ether, or ethyl acetate, and the "14-deoxyandrographolide, etc." contained or extracted is mixed thoroughly and almost uniformly with a stirrer or the like in a range not exceeding 100% by weight in total, with 0.0001% to 99.9999% by weight of water, alcohol, oils and fats that are liquid at room temperature, acetone, petroleum ether, or ethyl acetate. This is also a method for producing a composition for treating glaucoma.
[0044] The above-mentioned Andrographis paniculata may be washed with water, alcohol, oil, acetone, petroleum ether, ethyl acetate, etc., and finely cut or powdered with a cutter, grinder, crusher, powderer, etc., to obtain the above-mentioned "andrographolide (diterpene lactone) etc." or "14-deoxyandrographolide etc.". This content contains 0.001% by weight to 99.999% by weight of water, etc. The content may be further mixed sufficiently and almost uniformly with a stirrer, etc., within a range not exceeding 100% by weight in total, or may not be stirred. The method for producing such a content is also a method for producing a composition for treating glaucoma.
[0045] Such mixtures can be taken orally as they are, or can be taken in capsules such as gelatin, or diluted with distilled water and used as eye drops, in which case the above alcohol, oil, acetone, petroleum ether, and ethyl acetate are completely removed.
[0046] (3) Extract from Andrographis paniculata (production method) Andrographolide (diterpene lactone), extracted and separated from Andrographis paniculata as described above, has the chemical formula shown in Chemical Formula 1 below, and is used as an autophagy inducer that induces cell death accompanied by autophagy (type II cell death), as well as for the treatment and improvement of glaucoma.
[0047] In addition, the numbers in the above and following chemical formulae are normally written in small letters at the bottom right of each chemical symbol, but in this application, they are written in large letters in normal half-width size for ease of viewing. Solid arrows, dashed arrows, and dotted arrows indicate atoms or atomic groups that cause nucleophilic substitution and atoms or atomic groups that are nucleophilically substituted, and are usually represented by thin, elongated triangular lines that go from thick to thin, but in this application, they are represented by solid arrows, dashed arrows, and dotted arrows for convenience.
[0048] The numbers in the chemical formulas indicate the chemical equivalents in a chemical reaction. The difference between solid and dashed / dotted lines in the chemical formulas indicates the difference between ionic and covalent bonds. [ka] The chemical formula of this "chemical formula 1" is the above-mentioned andrographolide (diterpene lactone) (also called andrographolide). It has been shown to be effective in treating and improving glaucoma. [ka]
[0049] The chemical formula of this "chemical formula 2" is 14-deoxyandrographolide. It has immunomodulatory, anti-atherogenic, and anti-arteriosclerotic properties. It has also been shown to be effective in treating and improving glaucoma. In the above composition for treating glaucoma, 14-deoxyandrographolide may be mixed almost uniformly alone in the range of 0.0001% by weight to 99.9999% by weight, not exceeding 100% by weight in total, or may be mixed with the above andrographolide.
[0050] The above-mentioned immunomodulatory property is a property that prevents the immune system from becoming too strong or too weak, and keeps the immune system normal. The above-mentioned anti-atheromatous property is a property that prevents atheromas, which are retention cysts of hair follicles or sebaceous glands that occur subcutaneously and contain a porridge-like substance made of fat and keratinized epidermis, and which sometimes become inflamed and spontaneously burst. The above-mentioned anti-arteriosclerotic property is a property that prevents diseases in which cholesterol and other substances are deposited in the arterial walls, destroying the tissue, causing the walls to thicken and harden, losing their elasticity and becoming brittle. [ka]
[0051] The chemical formula of this "Chemical formula 3" is neoandrographolide. It has anti-inflammatory, anti-infective, and anti-hepatotoxic properties. It has also been shown to be effective in treating and improving glaucoma. In the above-mentioned composition for treating glaucoma, neoandrographolide may be mixed almost uniformly in the range of 0.0001% by weight to 99.9999% by weight, not exceeding 100% by weight in total, or may be mixed with the above-mentioned andrographolide or 14-deoxyandrographolide. The "Glc" connected to the "O" in this chemical formula of "Chemical formula 3" represents various monosaccharides.
[0052] The anti-inflammatory properties mentioned above include the body's defense reaction to suppress redness, swelling, burning heat, pain, and other symptoms that occur in parts of the body in response to tissue damage caused by bacterial infection, chemical action, physical action, etc., and to expel the intrusion of foreign substances or tissues that have become foreign bodies.
[0053] The above-mentioned anti-infective properties are properties that prevent infectious diseases and illnesses caused by infection with bacteria, viruses, fungi, parasites, protozoa, etc. The above-mentioned anti-hepatotoxic properties are properties that prevent the liver's functions of synthesis, storage, and decomposition of glycogen, blood sugar secretion, synthesis of plasma proteins, detoxification, and production and secretion of bile from being hindered due to liver dysfunction. [ka]
[0054] The chemical formula of this "chemical formula 4" is 14-deoxy-11,12-didehydroandrographolide. It has anti-immunostimulatory, anti-infective, anti-atheromatous, and anti-arteriosclerotic properties. It has also been found to be effective in treating and improving glaucoma. In the above composition for treating glaucoma, 14-deoxy-11,12-didehydroandrographolide may be mixed almost uniformly alone in the range of 0.0001% by weight to 99.9999% by weight, not exceeding 100% by weight in total, or may be mixed with the above andrographolide, 14-deoxyandrographolide, or neoandrographolide.
[0055] The above-mentioned anti-immunostimulatory property is a property that prevents the immune system from responding strongly or weakly to some kind of stimulus, thereby keeping the immune response within a normal range. The anti-infective, anti-atherogenic, and anti-arteriosclerotic properties are as described above. [ka]
[0056] The chemical formula of this "Chemical formula 5" is 14-deoxy-14,15-dehydroandrographolide. It has anti-inflammatory properties. This anti-inflammatory property is as described above. It has also been found to be effective in treating and improving glaucoma. In the composition for treating glaucoma, this 14-deoxy-14,15-dehydroandrographolide may be mixed almost uniformly alone in the range of 0.0001% by weight to 99.9999% by weight, not exceeding 100% by weight in total, or may be mixed with the andrographolide, 14-deoxyandrographolide, neoandrographolide, or 14-deoxy-11,12-didehydroandrographolide. [ka]
[0057] The chemical formula of this "Chemical formula 6" is andrographin. It has anti-inflammatory and anti-infective properties. The anti-inflammatory and anti-infective properties are as described above. It has also been found to be effective in treating and improving glaucoma. In the composition for treating glaucoma, this andrographin may be mixed almost uniformly in the range of 0.0001% by weight to 99.9999% by weight, not exceeding 100% by weight in total, alone, or may be mixed with the andrographolide, or may be mixed with the andrographolide, 14-deoxyandrographolide, neoandrographolide, 14-deoxy-11,12-didehydroandrographolide, or 14-deoxy-14,15-dehydroandrographolide. [ka]
[0058] The chemical formula of this "Chemical formula 7" is isoandrographolide. It has an antitumor effect. It has also been found to be effective in treating and improving glaucoma. In the composition for treating glaucoma, this isoandrographolide may be mixed almost uniformly alone in a range of 0.0001% by weight to 99.9999% by weight, not exceeding 100% by weight in total, or may be mixed with the andrographolide, 14-deoxyandrographolide, neoandrographolide, 14-deoxy-11,12-didehydroandrographolide, 14-deoxy-14,15-dehydroandrographolide, or andrographin.
[0059] This antitumor effect is a property that prevents the excessive proliferation of somatic cells, which often form localized nodules in organs and tissues as swellings or lumps. Tumors are classified as epithelial or non-epithelial depending on the originating cells, and benign (adenoma, lipoma, fibroma, osteoma, etc.) or malignant (sarcoma, carcinoma, etc.) depending on the nature of tumor proliferation. [ka]
[0060] The chemical formula of this "chemical formula 8" is 14-acetylandrographolide. It has an antitumor effect. This antitumor effect is as described above. It has also been found to be effective in treating and improving glaucoma. In the composition for treating glaucoma, 14-acetylandrographolide may be mixed almost uniformly alone in the range of 0.0001% by weight to 99.9999% by weight, not exceeding 100% by weight in total, or may be mixed with the andrographolide, 14-deoxyandrographolide, neoandrographolide, 14-deoxy-11,12-didehydroandrographolide, 14-deoxy-14,15-dehydroandrographolide, andrographin, or isoandrographolide. [ka]
[0061] The chemical formula of this "Chemical formula 9" is 3,19-isopropylideneandrographolide. It has an antitumor effect. This antitumor effect is as described above. It has also been found to be effective in treating and improving glaucoma. In the composition for treating glaucoma, this 3,19-isopropylideneandrographolide may be mixed almost uniformly alone in the range of 0.0001% by weight to 99.9999% by weight, not exceeding 100% by weight in total, or may be mixed with the above andrographolide, 14-deoxyandrographolide, neoandrographolide, 14-deoxy-11,12-didehydroandrographolide, 14-deoxy-14,15-dehydroandrographolide, andrographin, isoandrographolide, or 14-acetylandrographolide. The "Ac" connected to the "O" in the chemical formulas "Chemical Formula 8" and "Chemical Formula 9" above represents various glycans.
[0062] [ka] The chemical formula of this "chemical formula 10" is the above-mentioned 5-hydroxy-7,8-dimethoxyflavone. It has been shown to be effective in treating and improving glaucoma.
[0063] [ka] The chemical formula of this "chemical formula 11" is the above-mentioned 5-hydroxy-7,8-dimethoxyflavone. It has been shown to be effective in treating and improving glaucoma. The substance of this "chemical formula 11" has only one double bond instead of a single bond compared to the above-mentioned "chemical formula 10", and the chemical properties are similar, and the efficacy and effects of treating and improving glaucoma are also similar.
[0064] [ka] The chemical formula of this compound is 5-hydroxy-7,8,2',5'-tetramethoxiflavone. It has been shown to be effective in treating and improving glaucoma.
[0065] [ka] The chemical formula of this compound is 5-hydroxy-7,8,2',3'-tetramethoxiflavone. It has been shown to be effective in treating and improving glaucoma.
[0066] (4) Examples of efficacy and effectiveness of andrographolide (diterpene lactone) for glaucoma The following efficacy and effects have been observed when the above-mentioned andrographolide (diterpene lactone) (andrographolide), 14-deoxyandrographolide, neoandrographolide, 14-deoxy-11,12-didehydroandrographolide, 14-deoxy-14,15-dehydroandrographolide, andrographin, isoandrographolide, 14-acetylandrographolide, 3,19-isopropylideneandrographolide, 5-hydroxy-7,8-dimethoxyflavone, 5-hydroxy-7,8,2',5'-tetramethoxyflavone, and 5-hydroxy-7,8,2',3'-tetramethoxyflavone are orally administered to the human body, and further when used as an external composition for eye use.
[0067] (A) A woman in Hiroshima City was given 300μM (micromolar) of the above-mentioned andrographolide (diterpene lactone) (andrographolide) in a gelatin capsule, which she took orally for 95 days, 5 capsules at a time, 3 times a day, for a total of 15 capsules per day. She also received eye drops of the same ingredient diluted 100 to 1000 times with distilled water, 3 times a day for 95 days. As a result, her intraocular pressure dropped from 26, which was caused by glaucoma, to 17, and her abnormal high intraocular pressure dropped to almost normal, improving her intraocular pressure. She also reported that her eyes, which had previously complained of difficulty seeing, felt more comfortable and her vision became clearer and sharper.
[0068] (B) An elderly male was orally administered 300 μM (micromolar) of the above 14-deoxyandrographolide in a gelatin capsule, 5 capsules per time, 3 times a day, for a total of 15 capsules per day, for 95 days. In addition, this ingredient was diluted 100 to 1000 times with distilled water and instilled into the eyes 3 times a day for 95 days. As a result, the intraocular pressure, which was caused by glaucoma, dropped from 30 to 17, and the abnormal high intraocular pressure dropped to almost normal, improving the intraocular pressure abnormality. The patient's vision, which had been poor, became more comfortable and the field of vision became clearer and sharper.
[0069] (C) An elderly woman was given 300μM (micromolar) of the above neoandrographolide in a gelatin capsule, which was administered orally for 85 days, with 5 capsules administered at a time, 3 times a day, for a total of 15 capsules per day. Additionally, this ingredient was diluted 100 to 1000 times with distilled water and instilled into her eyes 3 times a day for 85 days. As a result, her intraocular pressure, which had been caused by glaucoma, dropped from 27 to 18, and her abnormal high intraocular pressure dropped to almost normal, improving her intraocular pressure. The woman's eyes, which had previously complained of difficulty seeing, became more comfortable, and she was able to see clearly and sharply.
[0070] (D) An elderly woman was orally administered 300 μM (micromolar) of the above 14-deoxy-11,12-didehydroandrographolide in a gelatin capsule, 5 capsules per time, 3 times a day, for a total of 15 capsules per day, for 90 days. In addition, this ingredient was diluted 100 to 1000 times with distilled water and instilled into her eyes 3 times a day for 90 days. As a result, her intraocular pressure, which was caused by glaucoma, dropped from 26 to 15, and her abnormal high intraocular pressure dropped to almost normal, improving her intraocular pressure. The woman commented that her eyes, which had previously complained of difficulty seeing, became more comfortable and her vision became clearer and sharper.
[0071] (E) A man in Okayama Prefecture orally took 300 μM (micromolar) of the above 14-deoxy-14,15-dehydroandrographolide in a gelatin capsule for 100 days, five capsules at a time, twice a day, for a total of 10 capsules per day. He also administered a 100-1000-fold dilution of the ingredient with distilled water three times a day for 100 days. As a result, his intraocular pressure dropped from 35 to 18, which was caused by glaucoma, and his vision became almost normal. The man commented that his vision, which he had previously complained of being difficult to see, became more comfortable, his headaches disappeared, and his vision became clearer and sharper.
[0072] (F) An elderly woman was given 300 μM (micromolar) of the above-mentioned andrographin in a gelatin capsule, which was administered orally for 85 days, with 5 capsules administered at a time, 3 times a day, for a total of 15 capsules per day. Additionally, this ingredient was diluted 100 to 1000 times with distilled water and instilled into her eyes 3 times a day for 85 days. As a result, her intraocular pressure, which had been caused by glaucoma, dropped from 26 to 15, and her abnormal high intraocular pressure dropped to almost normal, improving her intraocular pressure. The woman commented that her eyes, which had previously complained of difficulty seeing, became more comfortable and her vision became clearer and sharper.
[0073] (G) An elderly male was orally administered 300 μM (micromolar) of the above-mentioned isoandrographolide in a gelatin capsule, 5 capsules per time, 3 times a day, for a total of 15 capsules per day, for 90 days. In addition, this ingredient was diluted 100 to 1000 times with distilled water and instilled into the eyes 3 times a day for 90 days. As a result, the intraocular pressure, which was caused by glaucoma, dropped from 33 to 17, and the abnormal high intraocular pressure dropped to almost normal, improving the intraocular pressure abnormality. The patient's vision, which had been poor, became more comfortable, his headache disappeared, and he could see clearly.
[0074] (H) An elderly male was orally administered 300 μM (micromolar) of the above 14-acetylandrographolide in a gelatin capsule, four capsules at a time, three times a day, for a total of 12 capsules per day, for 95 days. In addition, the compound was diluted 100 to 1000 times with distilled water and instilled into his eyes three times a day for 95 days. As a result, the intraocular pressure, which was caused by glaucoma, dropped from 30 to 15, and the abnormal high intraocular pressure dropped to almost normal, improving the intraocular pressure abnormality. The patient's vision, which had been poor, became more comfortable, and he was able to see clearly and steadily.
[0075] (I) A man in Kagawa Prefecture orally took 300 μM (micromolar) of the above-mentioned 3,19-isopropylideneandrographolide in a gelatin capsule for 80 days, taking 5 capsules at a time, 3 times a day, for a total of 15 capsules per day. In addition, the same ingredient was diluted 100 to 1000 times with distilled water and instilled into his eyes 3 times a day for 80 days. As a result, his intraocular pressure, which was caused by glaucoma, dropped from 35 to 18, and his abnormal high intraocular pressure dropped to almost normal. His abnormal intraocular pressure improved, and he reported that his eyes, which had previously been experiencing difficulty seeing, became more comfortable, his headaches disappeared, and he could see clearly.
[0076] Improvement of retinal damage or visual field damage (M) For an elderly male, 300μM (micromolar) of the above-mentioned andrographolide (diterpene lactone) (andrographolide) was orally administered for 95 days, with 5 capsules per time, 3 times a day, for a total of 15 capsules per day. Furthermore, this ingredient was diluted 100 to 1000 times with distilled water and instilled into the eyeball 3 times a day for 95 days. As shown in Figure 1 (M1), visual field abnormalities were observed on the left side of the visual field due to glaucoma, but as shown in the upper part of the abnormal range in Figure 1 (M2), the range of visual field abnormalities was reduced, and the parts of the retina of the eye where the optic nerve was damaged or the visual field was damaged were improved. The intraocular pressure before and after the treatment were both "within the normal range."
[0077] (N) A man in Tokyo was orally administered 14-deoxyandrographolide at 300μM (micromolar) in a gelatin capsule, 5 capsules per time, 3 times a day, totaling 15 capsules per day, for 105 days, and then this ingredient was diluted 100 to 1000 times with distilled water and instilled into his eyeball 3 times a day for 105 days. As shown in Figure 2 (N1), visual field abnormalities were observed in the upper part of the visual field due to glaucoma, but as shown in the left side of the abnormal range in Figure 2 (N2), the range of visual field abnormalities was reduced, and the parts of the optic nerve of the retina of the eyeball or the visual field disorder were improved. The intraocular pressure before and after the treatment were both "within the normal range."
[0078] (O) An elderly woman was orally administered 300μM (micromolar) of the above neoandrographolide in a gelatin capsule, 5 capsules per time, 3 times a day, totaling 15 capsules per day, for 100 days, and then this ingredient was diluted 100 to 1000 times with distilled water and instilled into her eyeball 3 times a day for 100 days. As shown in Figure 3(O1), visual field abnormality was observed on the right side of the visual field due to glaucoma, but as shown in the left end, upper edge, and lower edge of the abnormal range in Figure 3(O2), the range of visual field abnormality was reduced, and the area of the optic nerve of the retina of the eyeball or the visual field disorder was improved. The intraocular pressure before and after the treatment was "within the normal range."
[0079] (P) A middle-aged man was orally administered 14-deoxy-11,12-didehydroandrographolide at 300μM (micromolar) in a gelatin capsule, 5 capsules per time, 3 times a day, totaling 15 capsules per day, for 80 days, and then this ingredient was diluted 100 to 1000 times with distilled water and instilled into his eyeball 3 times a day for 80 days. As shown in Figure 4 (P1), visual field abnormalities were observed in the upper right corner of the visual field due to glaucoma, but as shown above and to the right of the abnormal range in Figure 4 (P2), the range of visual field abnormalities was reduced, and the areas of the optic nerve damage in the retina of the eyeball or the visual field damage were improved. The intraocular pressure before and after the treatment were both "within the normal range."
[0080] (Q) A woman in Kanagawa Prefecture was given 300μM (micromolar) of the above 14-deoxy-14,15-dehydroandrographolide in a gelatin capsule, which was administered orally for 95 days, 5 capsules per time, 3 times a day, for a total of 15 capsules per day. In addition, this ingredient was diluted 100 to 1000 times with distilled water and instilled into her eyes 3 times a day for 95 days. As shown in Figure 5 (Q1), visual field abnormalities were observed slightly to the right of the center of the visual field due to glaucoma, but as shown in the upper right of the abnormal range in Figure 5 (Q2), the range of visual field abnormalities was reduced, and the areas of the optic nerve damage in the retina of the eye or the visual field damage were improved. The intraocular pressure before and after the treatment were both "within the normal range."
[0081] (R) An elderly woman was orally administered 300μM (micromolar) of the above-mentioned andrographin in a gelatin capsule, 5 capsules per time, 3 times a day, totaling 15 capsules per day, for 110 days, and then this ingredient was diluted 100 to 1000 times with distilled water and instilled into the eyeball 3 times a day for 110 days. As shown in Figure 6 (R1), visual field abnormalities were observed in the lower part of the visual field due to glaucoma, but as shown at both ends of the lower edge of the abnormal range in Figure 6 (R2), the range of visual field abnormalities was reduced, and the parts of the retina of the eye where the optic nerve was damaged or the visual field was damaged were improved. The intraocular pressure before and after the treatment were both "within the normal range."
[0082] (S) A man in Shizuoka Prefecture was orally administered 300μM (micromolar) of the above isoandrographolide in a gelatin capsule, 5 capsules per time, 3 times a day, totaling 15 capsules per day, for 100 days. In addition, the ingredient was diluted 100 to 1000 times with distilled water and instilled into the eyeball 3 times a day for 100 days. As shown in Figure 7 (S1), visual field abnormalities were observed in the center of the visual field due to glaucoma, but as shown in the lower right of the abnormal range in Figure 7 (S2), the range of visual field abnormalities was reduced, and the parts of the retina of the eye where the optic nerve was damaged or the visual field was damaged were improved. The intraocular pressure before and after the treatment were both "within the normal range."
[0083] (T) A middle-aged man was orally administered 14-acetylandrographolide at 300μM (micromolar) in a gelatin capsule, 5 capsules per time, 3 times a day, totaling 15 capsules per day, for 95 days, and then this ingredient was diluted 100 to 1000 times with distilled water and instilled into his eyeball 3 times a day for 95 days. As shown in Figure 8 (T1), visual field abnormalities were observed near the center of the visual field due to glaucoma, but as shown in the upper right of the abnormal range in Figure 8 (T2), the range of visual field abnormalities was reduced, and the areas of the optic nerve damage in the retina of the eyeball or the visual field damage were improved. The intraocular pressure before and after the treatment were both "within the normal range."
[0084] (U) A middle-aged woman was orally administered 300μM (micromolar) of the above 3,19-isopropylideneandrographolide in a gelatin capsule, 5 capsules per time, 3 times a day, totaling 15 capsules per day, for 110 days, and then this ingredient was diluted 100 to 1000 times with distilled water and instilled into her eyes 3 times a day for 110 days. As shown in Figure 9 (U1), visual field abnormalities were observed in the center and slightly above the visual field due to glaucoma, but as shown near the right side of the abnormal range in Figure 9 (U2), the range of visual field abnormalities was reduced, and the areas of the optic nerve damage in the retina of the eye or the visual field damage were improved. The intraocular pressure before and after the treatment were both "within the normal range."
[0085] The following Figures 10 to 15 show measurements of the thickness of the macular retina in patients with glaucoma. If the macular retina is thick, there is no abnormality in vision, and if the thickness of the macular retina is thin, it is determined that there is a symptom of glaucoma and vision becomes abnormal. In Figures 10 to 15, the macular retina was divided into four equal parts in the radial direction, top, bottom, left, and right, and then further divided into two parts in a concentric circle around the center and its outer part, and the thickness of the macular retina was measured in a total of nine areas.
[0086] The macula is a slightly yellowish spot on the retina opposite the pupil, shaped like an oval with a diameter of 3 mm, with the fovea centralis in its center. It is the most visually sensitive part of the retina, and is also called the yellow spot. Figures 10 to 15 measure the thickness of the macular retina, which is sensitive to visual acuity, but the symptoms of glaucoma can be fully understood by measuring this sensitive part.
[0087] 10 to 15, in each region, if the macular retina is thick, for example, 50 μm or more, and there is no abnormality, it is marked as "white", if the thickness of the macular retina is thin, for example, 50 μm to 25 μm, and there is an abnormality in vision, it is marked as "gray", and if the thickness of the macular retina is significantly thin, for example, 25 μm or less, and there is a significant abnormality in vision, it is marked as "black". The thickness of the macular retina that is considered abnormal is an example, and may be changed depending on individual differences, age differences, gender differences, and the presence or absence of chronic diseases.
[0088] (V) For an elderly woman, 300μM (micromolar) of all the above compounds, including andrographolide (diterpene lactone), were orally administered for 102 days, six capsules per time, three times a day, for a total of 18 capsules per day. Furthermore, this ingredient was diluted 100-1000 times with distilled water and instilled into the eye for 102 days. As shown in Figure 10(V1), visual field abnormalities were observed from the right to the lower part of the visual field due to glaucoma, but as shown in the center lower part of the abnormal range in Figure 10(V2), the range of visual field abnormalities was reduced, and the parts of the retina of the eye where the optic nerve was damaged or the visual field was damaged were improved. Both intraocular pressures before and after the treatment were "within the normal range."
[0089] (W) A middle-aged woman was orally administered 300 μM (micromolar) of all the above compounds, including andrographolide (diterpene lactone), in a gelatin capsule, 5 capsules per time, 3 times a day, a total of 15 capsules per day, for 211 days, and then this ingredient was diluted 100 to 1000 times with distilled water and instilled into her eyeball 3 times a day for 211 days. As shown in Figure 11 (W1), visual field abnormalities were observed in almost the entire visual field due to glaucoma, but as shown below and in the center right of the abnormal range in Figure 11 (W2), the range of visual field abnormalities was reduced, and the parts of the retina of the eye where the optic nerve was damaged or the visual field was damaged were improved. The intraocular pressure before and after the treatment was normal, "13 to 14". An increase in the range of visual field abnormalities was observed in the center left of the visual field, but this is thought to be temporary, and overall, the range of decrease in the range of visual field abnormalities was greater than the range of increase in visual field abnormalities.
[0090] (X) A middle-aged woman was orally administered 300μM (micromolar) of all the above compounds, including andrographolide (diterpene lactone), in a gelatin capsule, 4 capsules per time, 3 times a day, totaling 12 capsules per day, for 103 days, and then this ingredient was diluted 100-1000 times with distilled water and instilled into her eyeball 3 times a day for 103 days. As shown in Figure 12 (X1), visual field abnormalities were observed from the right to the lower part of the visual field due to glaucoma, but as shown in the center lower part of the abnormal range in Figure 12 (X2), the range of visual field abnormalities was reduced, and the parts of the retina of the eye where the optic nerve was damaged or the visual field was damaged were improved. Both intraocular pressures before and after the treatment were "within the normal range."
[0091] (Y) For an elderly male, 300μM (micromolar) of the above 5-hydroxy-7,8-dimethoxyflavone was orally administered for 95 days, 5 capsules per time, 3 times a day, totaling 15 capsules per day, and this ingredient was also diluted 100-1000 times with distilled water and instilled into the eyeball 3 times a day for 95 days. As shown in Figure 13 (Y1), visual field abnormalities were observed from the upper to the right and downward due to glaucoma, but as shown in the center lower part of the abnormal range in Figure 13 (Y2), the range of visual field abnormalities was reduced, and the parts of the retina of the eye where the optic nerve was damaged or the visual field was damaged were improved. Both intraocular pressure before and after the treatment were "within the normal range."
[0092] (Z) A middle-aged woman was orally administered 5-hydroxy-7,8,2',5'-tetramethoxiflavone at 300μM (micromolar) in a gelatin capsule, 5 capsules per time, 3 times a day, totaling 15 capsules per day, for 152 days, and this ingredient was diluted 100-1000 times with distilled water and instilled into her eyes 3 times a day for 152 days. As shown in Figure 14(Z1), visual field abnormalities were observed from the right to the lower part of the visual field to the left due to glaucoma, but as shown to the left of the abnormal range in Figure 14(Z2), the range of visual field abnormalities was reduced, and the parts of the retina of the eye where the optic nerve was damaged or the visual field was damaged were improved. The intraocular pressure before and after the treatment were both "within the normal range."
[0093] (a) A middle-aged woman was orally administered 300 μM (micromolar) of the above 5-hydroxy-7,8,2',3'-tetramethoxiflavone in a gelatin capsule, 4 capsules per time, 3 times a day, totaling 12 capsules per day, for 121 days, and this ingredient was diluted 100 to 1000 times with distilled water and instilled into her eyeball 3 times a day for 121 days. As shown in Figure 15(a1), visual field abnormalities were observed from the left to the bottom of the visual field due to glaucoma, but as shown in the center left of the abnormal range in Figure 15(a2), the range of visual field abnormalities was reduced, and the parts of the retina of the eye where the optic nerve was damaged or the visual field was damaged were improved. Both intraocular pressures before and after the treatment were "within the normal range."
[0094] As described above, the efficacy and effects of the product can be further improved by mixing and formulating the above-mentioned andrographolide (diterpene lactone) (andrographolide), as well as the above-mentioned 14-deoxyandrographolide, neoandrographolide, 14-deoxy-11,12-didehydroandrographolide, 14-deoxy-14,15-dehydroandrographolide, andrographin, isoandrographolide, 14-acetylandrographolide, 3,19-isopropylideneandrographolide, 5-hydroxy-7,8-dimethoxyflavone, 5-hydroxy-7,8,2',5'-tetramethysiflavone, and / or 5-hydroxy-7,8,2',3'-tetramethysiflavone.
[0095] The composition for treating glaucoma may be prepared by mixing one, two, three, four, five or more types, or all of the above-mentioned andrographolide (diterpene lactone), 14-deoxyandrographolide, neoandrographolide, 14-deoxy-11,12-didehydroandrographolide, 14-deoxy-14,15-dehydroandrographolide, andrographin, isoandrographolide, 14-acetylandrographolide, 3,19-isopropylideneandrographolide, 5-hydroxy-7,8-dimethoxyflavone, 5-hydroxy-7,8,2',5'-tetramethoxyflavone, and 5-hydroxy-7,8,2',3'-tetramethoxyflavone.
[0096] The composition for treating glaucoma used here was 300 μM (micromolar) per capsule, but it may be more than or less than 300 μM per capsule. The amount to be taken at one time, daily, weekly, monthly, semi-annual, and annually may be increased or decreased depending on the severity (medium or mild) of glaucoma symptoms, and the age, weight, and sex of the person taking the composition.
[0097] The total amount of intake per time, day, week, month, half year, and year may be 0.0001 to 99.9999% by weight of the andrographolide (diterpene lactone) or the like, which may be powdered as is at 0.0001 to 99.9999% by weight, or may be mixed almost uniformly with 0.001 to 99.999% by weight of water, alcohol, or oils and fats that are liquid at room temperature, in a total amount not exceeding 100% by weight.
[0098] The concentration varies within the range of 0.0001% by weight to 99.9999% by weight depending on the severity of the symptoms, for example, 99.9999% by weight for severe glaucoma symptoms, 50% by weight for moderate symptoms, and 0.0001% by weight for mild symptoms. Similarly, the concentration varies within the range of 0.0001% by weight to 99.9999% by weight depending on the age, weight, and sex of the person who takes the composition. However, the same effect of variation can be obtained by increasing or decreasing the amount of the composition for treating glaucoma, the number of capsules, or the number of tablets taken while keeping the concentration constant.
[0099] Furthermore, if there is a large amount of water, alcohol or oil, the present composition for treating glaucoma is usually liquid. If the proportion of water, alcohol or oil is reduced, the present composition for treating glaucoma becomes sol-like or gel-like. If there is little or no water, alcohol or oil, the present composition for treating glaucoma becomes powder, powder or granular powder. The present composition for treating glaucoma is one of pharmaceutical compositions. The black areas near the center of the left and right of Figures 1 to 9 above are blind spots in the eyeball, and are not abnormalities of the retina or visual field.
[0100] The above-mentioned composition for treating glaucoma may contain added ingredients such as hardened rapeseed oil, gelatin, eggshell calcium, milk thistle extract powder, silymarin, Panax notoginseng, ginkgo biloba leaves, oyster meat extract, sucrose fatty acid esters, sodium, carbohydrates, lipids, and proteins.
[0101] When added to the eyeball, the above-mentioned concentration of 0.0001% to 99.9999% by weight is diluted 10 to 10,000 times with water, etc. In some cases, sodium chloride, potassium chloride, glucose, vitamin A, vitamin B6, vitamin E, sodium chondroitin sulfate, potassium aspartate, neostigmine methylsulfate, chlorpheniramine maleate potassium L-aspartate, tetrahydrozoline hydrochloride, epsilon-aminocaproic acid, etc. may be added to match / approximate the salt concentration of body fluids and blood in the living body.
[0102] (5) They penetrate the blood-brain barrier and blood-retinal barrier to reach the retina and brain. For the brain's metabolism to function normally, the amount of oxygen and glucose in the blood must be stable. The choroid plexus of the ventricles and the capillary beds in the brain act as molecular and ionic filters, preventing small molecules and ions from entering the brain, so most substances in the blood cannot enter the brain. This type of filtering function is called the "blood-brain barrier."
[0103] Many biological compounds, such as adrenal hormones and amino acids, are too large to pass through the blood-brain barrier quickly, and small molecules and ions are polar, or charged, and cannot cross the blood-brain barrier at all. This maintains the brain's chemical balance. The blood-brain barrier also protects the brain from abnormal chemicals that enter the body through food and drink.
[0104] The blood-retinal barrier, which has a similar function to the blood-brain barrier, exists between the pupil and retina of the eye, and normal substances cannot pass from the capillaries to the retina, or from the choroid or sclera of the eye to the retina. Therefore, normal drugs cannot reach the brain or retina.
[0105] However, the above-mentioned andrographolide (diterpene lactone), 14-deoxyandrographolide, neoandrographolide, 14-deoxy-11,12-didehydroandrographolide, 14-deoxy-14,15-dehydroandrographolide, andrographin, isoandrographolide, 14-acetylandrographolide, 3,19-isopropylideneandrographolide, 5-hydroxy-7,8-dimethoxyflavone, 5-hydroxy-7,8,2',5'-tetramethoxiflavone, and / or 5-hydroxy-7,8,2',3'-tetramethoxiflavone can pass through the "blood-retinal barrier" or "blood-brain barrier," and thus can reach the retina and treat the retina, or reach the brain, including the optic nerve, and treat the brain, including the optic nerve.
[0106] Since light information is transmitted from the retina of the eye to the brain via glutamate, it is significant that it can pass through not only the "blood-retinal barrier" but also the "blood-brain barrier." The results of this treatment are as explained in (4) above, and since it can reach the retina, optic nerve, and brain, a reduction in the range of visual field abnormalities is observed, and the areas of the retina of the eye that are suffering from optic nerve damage or visual field damage are improved.
[0107] (6) Other embodiments and examples The present invention is not limited to the above-mentioned embodiments, and some of the embodiments may be omitted without departing from the spirit of the present invention. For example, the water may be replaced with alcohol or oil, the water may be mixed with alcohol or oil, or the water may be free of alcohol or oil.
[0108] In this case, 0.001% by weight to 99.999% by weight, preferably 10% by weight to 80% by weight of water is mixed with 0.001% by weight to 99.999% by weight, preferably 10% by weight to 80% by weight of alcohol or 0.001% by weight to 99.999% by weight, preferably 10% by weight to 80% by weight of oil.
[0109] The above-mentioned andrographolide, etc. may be mixed and formulated with starch, lactose, gum arabic, or other fillers to form tablets, or may be mixed and formulated with liquid to form liquid preparations.
[0110] Among the above-mentioned andrographolide (diterpene lactone), 14-deoxyandrographolide, neoandrographolide, 14-deoxy-11,12-didehydroandrographolide, 14-deoxy-14,15-dehydroandrographolide, 14-deoxy-11,12-didehydroandrographolide, andrographin, 14-deoxy-11,12-didehydroandrographolide, 14-acetylandrographolide, and 3,19-isopropylideneandrographolide, 5-hydroxy-7,8-dimethoxyflavone, 5-hydroxy-7,8,2',5'-tetramethoxyflavone, and 5-hydroxy-7,8,2',3'-tetramethoxyflavone, one or more of them may be omitted from the composition for treating glaucoma and may not be mixed.
[0111] The above-mentioned andrographolide (diterpene lactone) may or may not contain deoxyandrographolide, neoandrographolide, homoandrographolide, and vanicolide from the leaves of Andrographis paniculata.Furthermore, the andrographolide (diterpene lactone) may or may not contain andrographosterin, β-sitosterol-D-glucoside, etc.
[0112] The above-mentioned andrographolide (diterpene lactone) may or may not contain, in addition to andrographolide, mono-O-methylweitin (5-hydroxy-7,8,2,3-tetramethoxyflavone), andrographin (5-hydroxyquincine-7,8,2-trimethoxyflavone), panicolin (5,2-dihydroxyquin-7,8-dimethoxyflavone), apigenin-7,4-dimethyl ether, α1-sitosterol, KH2PO4, etc., which are found in the roots of Andrographis paniculata.
[0113] The above-mentioned andrographolide (diterpene lactone) may or may not contain 14-deoxy-11-oxoandrographolide and 14-deoxy-11,12-didehydroandrographolide from the whole plant of Andrographis paniculata, in addition to andrographolide, and may or may not contain phenolic substances such as steroid saponins, sugars, and condensed tannins.
[0114] The above-mentioned andrographolide (diterpene lactone) includes various types such as 14-deoxy-andrographolide, 14-deoxy-11,12-dehydrogenandrographolide, and neoandrographolide.
[0115] The above-mentioned glaucoma therapeutic composition includes a variety of compositions, such as a paste glaucoma therapeutic composition, a powder glaucoma therapeutic composition, a liquid glaucoma therapeutic composition, a solid glaucoma therapeutic composition, a cream-like glaucoma therapeutic composition, a sol-like glaucoma therapeutic composition, a gel-like glaucoma therapeutic composition, a paste-like glaucoma therapeutic composition, a foam-like glaucoma therapeutic composition, and a syrup-like glaucoma therapeutic composition.
[0116] The chemical formula of the above-mentioned andrographolide (diterpene lactone) is as described above, and is also shown in the specification of JP-A-10-120510, etc. Examples of plants containing andrographolide (diterpene lactone) include Andrographolide radiata (Centella asiatica) and any other plant that contains andrographolide (diterpene lactone).
[0117] Anti-inflammatory agents are a general term for medicines and drugs that suppress inflammation. Inflammation itself is a local defense reaction triggered by the immune system when an undesirable stimulus occurs in biological tissues, such as the invasion of a foreign body or tissue damage. While they help the body eliminate non-self substances, they also have the property of causing a certain amount of damage and pain to the self, which is the body itself.
[0118] In medical treatment, it is necessary to suppress the disadvantages of inflammation when treating allergies in which inflammation caused by the body is excessively damaging, or when treating hornet stings and turtle moth stings caused by the injection of physiologically active substances that cause inflammation from the outside, and anti-inflammatory drugs are used for this purpose. They are mainly classified into two types: steroidal anti-inflammatory drugs and non-steroidal anti-inflammatory drugs.
[0119] Steroidal anti-inflammatory drugs are glucocorticoids, a type of adrenal cortex hormone, and synthetic glucocorticoids. Steroids have extremely strong anti-inflammatory effects. Many non-steroidal anti-inflammatory drugs (NSAIDs: Non Steroidal Antiinflammatory Drugs) have analgesic and antipyretic effects in addition to anti-inflammatory effects.
[0120] Nonsteroidal anti-inflammatory drugs can be further divided into acidic anti-inflammatory drugs and basic anti-inflammatory drugs. Acidic anti-inflammatory drugs are widely used and include aspirin, ibuprofen, and indomethacin. Acidic anti-inflammatory drugs inhibit cyclooxygenase (COX), an enzyme that synthesizes prostaglandins from arachidonic acid, thereby inhibiting the synthesis of leukotrienes and prostaglandins, which are types of chemical mediators, and suppressing inflammation.
[0121] Such anti-inflammatory agents include eucalyptus leaf oil and allantoin, which will be described later, as well as aspirin, ibuprofen, indomethacin, etc. The alcohols mentioned above include methanol, ethanol, propanol, butanol, hexane, lower alcohols, higher alcohols, etc. The oils mentioned above may be derived from plants such as cottonseed, rice bran, rapeseed, palm, soybean, corn, sesame, hexane, and other plant seeds and fruits, but may also include those derived from animals.
[0122] The liquid oil may be a liquid oil such as olive oil, jojoba oil, coconut oil, palm oil, castor oil, peppermint oil, almond oil, soybean oil, camellia oil, sesame oil, safflower oil, coconut oil, sunflower oil, corn oil, rice oil, rice bran oil, peanut oil, cottonseed oil, etc. Olive, jojoba, coconut, palm, castor, peppermint, almond, soybean, camellia, sesame, safflower, coconut, sunflower, corn, rice, rice bran, peanut, cottonseed, etc., may be filtered from the oil and discarded or may be left in the oil, water or alcohol.
[0123] The composition for treating glaucoma of the present invention is effective not only in humans but also in animals such as dogs, cats, cows, and horses, and reduces abnormal intraocular pressure to the normal range, or reduces the extent of visual field abnormalities, and improves areas of the optic nerve of the retina of the eye or areas of visual field impairment.
[0124] The composition for treating glaucoma includes andrographolide (diterpene lactone), 14-deoxyandrographolide, neoandrographolide, 14-deoxy-11,12-didehydroandrographolide, 14-deoxy-14,15-dehydroandrographolide, andrographin, isoandrographolide, 14-acetylandrographolide, 3,19-isopropylideneandrographolide, 5-hydroxy ... The mixture of 7,8-dimethoxyflavone, 5-hydroxy-7,8,2',5'-tetramethoxyflavone, and / or 5-hydroxy-7,8,2',3'-tetramethoxyflavone is 0.0001% to 99.9999% by weight, but may be less than 0.0001% by weight, for example 0.00001% by weight, 0.000001% by weight, 0.000001% by weight, 0.0000001% by weight, or may be more than 99.9999% by weight, or may be 100% by weight.
[0125] (7) Effects of other inventions [1] A composition for treating glaucoma, comprising andrographolide (a diterpene lactone), which can treat and improve glaucoma. [2] A composition for treating glaucoma, comprising 14-deoxyandrographolide, which can treat and improve glaucoma. [3] A composition for treating glaucoma, comprising neoandrographolide, which can treat and improve glaucoma. [4] A composition for treating glaucoma, comprising 14-deoxy-11,12-didehydroandrographolide, which can treat and improve glaucoma. [5] A composition for treating glaucoma, comprising 14-deoxy-14,15-dehydroandrographolide, which can treat and improve glaucoma. [6] A composition for treating glaucoma, comprising andrographin, which can treat and improve glaucoma. [7] A composition for treating glaucoma, comprising isoandrographolide, which can treat and improve glaucoma.
[0126] [8] A composition for treating glaucoma, which contains 14-acetylandrographolide. This can treat and improve glaucoma. [9] A composition for treating glaucoma, which contains 3,19-isopropylideneandrographolide. This can treat and improve glaucoma.
[10] A composition for treating glaucoma, which contains 5-hydroxy-7,8-dimethoxyflavone. This can treat and improve glaucoma.
[11] A composition for treating glaucoma, which contains 5-hydroxy-7,8,2',5'-tetramethosyflavone. This can treat and improve glaucoma.
[12] A composition for treating glaucoma, which contains 5-hydroxy-7,8,2',3'-tetramethosyflavone. This can treat and improve glaucoma.
[13] A method for producing a composition for treating glaucoma, comprising producing Panax serrata in a powder, powder or granular form, thereby making it possible to treat and improve glaucoma.
[0127]
[21] A composition for treating glaucoma, comprising andrographolide (diterpene lactone) and water, alcohol, or an oil or fat that is liquid at room temperature, mixed in a substantially uniform manner, thereby making it possible to treat and improve glaucoma.
[0128]
[22] The composition for treating glaucoma according to claim 21, characterized in that the andrographolide (diterpene lactone) passes through the blood-retinal barrier or the blood-brain barrier to reach the retina of the eyeball or the optic nerve of the brain, thereby enabling andrographolide (diterpene lactone) to reach the retina of the eyeball or the optic nerve of the brain, thereby treating and improving glaucoma.
[0129]
[23] The composition for treating glaucoma according to claim 21 or 22, further comprising 14-deoxyandrographolide mixed in substantially uniformly, thereby enabling the treatment and amelioration of glaucoma through the synergistic effects of andrographolide (diterpene lactone) and 14-deoxyandrographolide.
[0130]
[24] The composition for treating glaucoma according to claim 21, 22 or 23, further comprising neoandrographolide mixed in substantially uniformly. This allows for the treatment and amelioration of glaucoma through the synergistic effects of andrographolide (diterpene lactone), 14-deoxyandrographolide, and neoandrographolide.
[0131]
[25] The composition for treating glaucoma according to claim 21, 22, 23 or 24, further comprising 14-deoxy-11,12-didehydroandrographolide mixed therein almost uniformly, thereby enabling the treatment and amelioration of glaucoma through the synergistic effects of andrographolide (diterpene lactone), 14-deoxyandrographolide, neoandrographolide and 14-deoxy-11,12-didehydroandrographolide.
[0132]
[26] The composition for treating glaucoma according to claim 21, 22, 23, 24 or 25, further comprising 14-deoxy-14,15-dehydroandrographolide mixed therein almost uniformly, thereby enabling the treatment and amelioration of glaucoma through the synergistic effects of andrographolide (diterpene lactone), 14-deoxyandrographolide, neoandrographolide, 14-deoxy-11,12-didehydroandrographolide, and 14-deoxy-14,15-dehydroandrographolide.
[0133]
[27] The composition for treating glaucoma according to claim 21, 22, 23, 24, 25 or 26, further comprising andrographin substantially uniformly mixed therein, thereby enabling the treatment and amelioration of glaucoma through the synergistic effects of andrographolide (diterpene lactone), 14-deoxyandrographolide, neoandrographolide, 14-deoxy-11,12-didehydroandrographolide, 14-deoxy-14,15-dehydroandrographolide, and andrographin.
[0134]
[28] The composition for treating glaucoma according to claim 21, 22, 23, 24, 25, 26 or 27, further comprising isoandrographolide mixed in a substantially uniform manner, thereby enabling the treatment and amelioration of glaucoma through the synergistic effects of andrographolide (diterpene lactone), 14-deoxyandrographolide, neoandrographolide, 14-deoxy-11,12-didehydroandrographolide, 14-deoxy-14,15-dehydroandrographolide, andrographin as well as isoandrographolide.
[0135]
[29] The composition for treating glaucoma according to claim 21, 22, 23, 24, 25, 26, 27 or 28, further comprising 14-acetylandrographolide mixed in the composition almost uniformly, thereby enabling the treatment and amelioration of glaucoma through the synergistic effects of andrographolide (diterpene lactone), 14-deoxyandrographolide, neoandrographolide, 14-deoxy-11,12-didehydroandrographolide, 14-deoxy-14,15-dehydroandrographolide, andrographin, isoandrographolide, and 14-acetylandrographolide.
[0136]
[30] The composition for treating glaucoma according to claim 21, 22, 23, 24, 25, 26, 27, 28 or 29, further comprising 3,19-isopropylideneandrographolide mixed in a substantially uniform manner, thereby enabling the treatment and amelioration of glaucoma through the synergistic effects of andrographolide (diterpene lactone), 14-deoxyandrographolide, neoandrographolide, 14-deoxy-11,12-didehydroandrographolide, 14-deoxy-14,15-dehydroandrographolide, andrographin, isoandrographolide, 14-acetylandrographolide, and 3,19-isopropylideneandrographolide.
[0137]
[31] A composition for treating glaucoma as described in any one of claims 21 to 30, characterized in that the andrographolide (diterpene lactone), 14-deoxyandrographolide, neoandrographolide, 14-deoxy-11,12-didehydroandrographolide, 14-deoxy-14,15-dehydroandrographolide, andrographin, isoandrographolide, 14-acetylandrographolide, and / or 3,19-isopropylideneandrographolide are mixed in an amount of 0.0001% by weight to 99.9999% by weight, and water, alcohol, or oils and fats that are liquid at room temperature are mixed in an amount of 0.001% by weight to 99.999% by weight, the total of which does not exceed 100% by weight, and are mixed almost uniformly. This allows each of these components to treat and improve glaucoma.
[0138]
[32] A method for producing a composition for treating glaucoma, comprising mixing andrographolide (diterpene lactone) with water, alcohol, or an oil or fat that is liquid at room temperature to a substantially uniform degree, thereby making it possible to treat and improve glaucoma and produce a composition for treating glaucoma.
[0139]
[33] The composition for treating glaucoma according to claim 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 or 31, which is orally administered, thereby making it possible to treat and improve glaucoma by oral administration.
[0140]
[34] The composition for treating glaucoma according to claim 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 or 31, which is added to an eyeball, thereby making it possible to treat and improve glaucoma by adding the composition to an eyeball.
[0141]
[35] The composition for treating glaucoma according to claim 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 or 31, characterized in that the composition for treating glaucoma reduces intraocular pressure in the eyeball, thereby reducing abnormal intraocular pressure to the normal range and treating and improving glaucoma.
[0142]
[36] The composition for treating glaucoma according to claim 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 or 31, characterized in that the composition improves a part of the retina of the eyeball where the optic nerve is damaged or where the visual field is impaired, thereby reducing the range of visual field abnormalities and improving the part of the retina of the eyeball where the optic nerve is damaged or where the visual field is impaired, thereby treating and improving glaucoma. [Industrial Applicability]
[0143] Andrographolide (diterpene lactone), 14-deoxyandrographolide, neoandrographolide, 14-deoxy-11,12-didehydroandrographolide, 14-deoxy-14,15-dehydroandrographolide, andrographin, isoandrographolide, 14-acetylandrographolide, 3,19-isopropylideneandrographolide, 3,19-isopropylideneandrographolide, 14-acetylandrographolide, 3,19-isopropylideneandrographolide, 5-hydroxy-7,8-dimethoxyflavone, etc. are powdered. By taking this, intraocular pressure is reduced to the normal range, and even if intraocular pressure is within the normal range, the range of visual field abnormalities is reduced, and the parts of the retina of the eye that are damaged by optic nerve or visual field are improved.
[0144] The composition is a substantially uniform mixture of 0.0001% by weight to 99.9999% by weight of andrographolide (diterpene lactone), 14-deoxyandrographolide, neoandrographolide, 14-deoxy-11,12-didehydroandrographolide, 14-deoxy-14,15-dehydroandrographolide, 14-deoxy-11,12-didehydroandrographolide, andrographin, isoandrographolide, 14-acetylandrographolide, or 3,19-isopropylideneandrographolide, 14-acetylandrographolide, 3,19-isopropylideneandrographolide, and 5-hydroxy-7,8-dimethoxyflavone, and 0.001% by weight to 99.999% by weight of water, alcohol, or oils and fats that are liquid at room temperature.
[0145] Glaucoma is treated and improved by a composition for treating glaucoma that contains andrographolide (diterpene lactone) etc. As a result, intraocular pressure is reduced to the normal range by andrographolide etc., and even when intraocular pressure is within the normal range, the range of visual field abnormalities is reduced, and the parts of the retina of the eye that are damaged by the optic nerve or visual field are improved.
Claims
1. A composition for treating glaucoma, comprising andrographolide (a diterpene lactone).
2. 2. The composition for treating glaucoma according to claim 1, which comprises 14-deoxyandrographolide.
3. 2. The composition for treating glaucoma according to claim 1, comprising neoandrographolide.
4. 2. The composition for treating glaucoma according to claim 1, which comprises 14-deoxy-11,12-didehydroandrographolide.
5. 2. The composition for treating glaucoma according to claim 1, which comprises 14-deoxy-14,15-dehydroandrographolide.
6. 2. The composition for treating glaucoma according to claim 1, which comprises andrographin.
7. 2. The composition for treating glaucoma according to claim 1, comprising isoandrographolide.
8. 2. The composition for treating glaucoma according to claim 1, which comprises 14-acetylandrographolide.
9. 2. The composition for treating glaucoma according to claim 1, which comprises 3,19-isopropylideneandrographolide.
10. 2. The composition for treating glaucoma according to claim 1, which comprises 5-hydroxy-7,8-dimethoxyflavone.
11. 2. The composition for treating glaucoma according to claim 1, which comprises 5-hydroxy-7,8,2',5'-tetramethoxiflavone.
12. 2. The composition for treating glaucoma according to claim 1, which comprises 5-hydroxy-7,8,2',3'-tetramethoxiflavone.
13. 2. The method for producing a composition for treating glaucoma according to claim 1, characterized in that the Radix Panax notoginseng is in the form of powder, dust or granules.
Citation Information
Patent Citations
Cleaning agent for oral cavity and preparation method thereof
CN102058502A
Drive mechanism for focal plane shutter of accordion type
JP1978057027A
High frequency heater
JP1982065687A
Production of water-in-oil type polyurethane resin
JP1987025113A
Waterproof treatment of fiber product
JP1987045786A
